

Литература к разделу «[Интегративный Проект Микробиом Человека](#)»

---

1. Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. *Science* **308**, 1635–1638 (2005).
  2. Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. *Science* **312**, 1355–1359 (2006).
  3. Costello, E. K. et al. Bacterial community variation in human body habitats across space and time. *Science* **326**, 1694–1697 (2009).
  4. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell* **155**, 1451–1463 (2013).
  5. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* **359**, 97–103 (2018).
  6. Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science* **359**, 104–108 (2018).
  7. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science* **359**, 91–97 (2018).
  8. Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium *Eggerthella lenta*. *Science* **341**, 295–298 (2013).
  9. Taur, Y. et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. *Blood* **124**, 1174–1182 (2014).
  10. Schloissnig, S. et al. Genomic variation landscape of the human gut microbiome. *Nature* **493**, 45–50 (2013).
  11. Franzosa, E. A. et al. Identifying personal microbiomes using metagenomic codes. *Proc. Natl Acad. Sci. USA* **112**, E2930–E2938 (2015).
  12. Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl Acad. Sci. USA* **107**, 11971–11975 (2010).
  13. Koenig, J. E. et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc. Natl Acad. Sci. USA* **108**, 4578–4585 (2010).
  14. Vatanen, T. et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature* **562**, 589–594 (2018).
  15. Yatsunencko, T. et al. Human gut microbiome viewed across age and geography. *Nature* **486**, 222–227 (2012).
  16. Pasolli, E. et al. Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. *Cell* **176**, 649–662.e620, (2019).
  17. Faith, J. J. et al. The long-term stability of the human gut microbiota. *Science* **341**, 1237439 (2013).
  18. Gajer, P. et al. Temporal dynamics of the human vaginal microbiota. *Sci. Transl. Med.* **4**, 132ra152 (2012).
  19. Gevers, D. et al. The Human Microbiome Project: a community resource for the healthy human microbiome. *PLoS Biol.* **10**, e1001377 (2012).
  20. Turnbaugh, P. J. et al. The Human Microbiome Project. *Nature* **449**, 804–810 (2007).
  21. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* **486**, 207–214 (2012). **HMP1 study analysing 5,177 16S rRNA gene sequencing profiles and 681 shotgun metagenomes spanning up to 18 body sites and three time points each from 242 healthy adults; established baseline ranges of taxonomic diversity within and between body sites, as well as strain personalization and functional commonalities.**
-

22. Human Microbiome Project Consortium. A framework for human microbiome research. *Nature* **486**, 215–221 (2012).
  23. Lloyd-Price, J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. *Nature* **550**, 61–66 (2017). **Second wave of HMP1 data (HMP1-II) extending the analysis and data resource to 2,355 total shotgun metagenomes from 265 healthy adults; quantified strain personalization and retention dynamics over time, as well as identifying niche-specific and host-associated microbial community functions.**
  24. Ravel, J. et al. Vaginal microbiome of reproductive-age women. *Proc. Natl Acad. Sci. USA* **108**, 4680–4687 (2011).
  25. Fettweis, J. M. et al. Differences in vaginal microbiome in African American women versus women of European ancestry. *Microbiology* **160**, 2272–2282 (2014).
  26. Kong, H. H. et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res.* **22**, 850–859 (2012).
  27. Alekseyenko, A. V. et al. Community differentiation of the cutaneous microbiota in psoriasis. *Microbiome* **1**, 31 (2013).
  28. Wylie, K. M., Mihindukulasuriya, K. A., Sodergren, E., Weinstock, G. M. & Storch, G. A. Sequence analysis of the human virome in febrile and afebrile children. *PLoS One* **7**, e27735 (2012).
  29. Lewis, J. D. et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. *Cell Host Microbe* **18**, 489–500 (2015).
  30. Zupancic, M. L. et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. *PLoS One* **7**, e43052 (2012).
  31. Erickson, A. R. et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn’s disease. *PLoS One* **7**, e49138 (2012).
  32. Frank, D. N. et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. *Inflamm. Bowel Dis.* **17**, 179–184 (2011).
  33. La Rosa, P. S. et al. Patterned progression of bacterial populations in the premature infant gut. *Proc. Natl Acad. Sci. USA* **111**, 12522–12527 (2014).
  34. Fodor, A. A. et al. The “most wanted” taxa from the human microbiome for whole genome sequencing. *PLoS One* **7**, e41294 (2012).
  35. Nelson, K. E. et al. A catalog of reference genomes from the human microbiome. *Science* **328**, 994–999 (2010).
  36. Wylie, K. M. et al. Novel bacterial taxa in the human microbiome. *PLoS One* **7**, e35294 (2012).
  37. Li, K., Bihan, M., Yooseph, S. & Methé, B. A. Analyses of the microbial diversity across the human microbiome. *PLoS One* **7**, e32118 (2012).
  38. Aagaard, K. et al. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. *FASEB J.* **27**, 1012–1022 (2013).
  39. Schloss, P. D., Gevers, D. & Westcott, S. L. Reducing the effects of PCR amplification and sequencing artifacts on 16S rRNA-based studies. *PLoS One* **6**, e27310 (2011).
  40. Jumpstart Consortium Human Microbiome Project Data Generation Working Group. Evaluation of 16S rDNA-based community profiling for human microbiome research. *PLoS One* **7**, e39315 (2012).
  41. Gevers, D., Pop, M., Schloss, P. D. & Huttenhower, C. Bioinformatics for the Human Microbiome Project. *PLoS Comput. Biol.* **8**, e1002779 (2012).
-

42. Huse, S. M., Ye, Y., Zhou, Y. & Fodor, A. A. A core human microbiome as viewed through 16S rRNA sequence clusters. *PLoS One* **7**, e34242 (2012).
  43. Markowitz, V. M. et al. IMG/M-HMP: a metagenome comparative analysis system for the Human Microbiome Project. *PLoS One* **7**, e40151 (2012).
  44. Cantarel, B. L., Lombard, V. & Henrissat, B. Complex carbohydrate utilization by the healthy human microbiome. *PLoS One* **7**, e28742 (2012).
  45. Rho, M., Wu, Y. W., Tang, H., Doak, T. G. & Ye, Y. Diverse CRISPRs evolving in human microbiomes. *PLoS Genet.* **8**, e1002441 (2012).
  46. Faust, K. et al. Microbial co-occurrence relationships in the human microbiome. *PLoS Comput. Biol.* **8**, e1002606 (2012).
  47. Abubucker, S. et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. *PLoS Comput. Biol.* **8**, e1002358 (2012).
  48. Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. *Cell Host Microbe* **16**, 276–289 (2014).
  49. Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature* <https://doi.org/10.1038/s41586-019-1237-9> (2019). **HMP2 Inflammatory Bowel Disease Multi-omics Database (IBDMDB) study profiling 2,965 stool, biopsy, and blood specimens from 132 individuals with Crohn’s disease, ulcerative colitis or neither (control subjects) followed longitudinally for one year each; multi-omic profiling identified taxa, expressed functions, metabolite pools, and host gene expression that were disrupted in the gut during increased disease activity, as well as systemic effects such as serum antibody levels.**
  50. Fettweis, J. M. et al. The vaginal microbiome and preterm birth. *Nat. Med.* <https://doi.org/10.1038/s41591-019-0450-2> (2019). **HMP2 preterm birth study of 1,527 pregnancies focusing on 45 spontaneous preterm birth events and 90 case-matched controls, together yielding over 12,000 multi-omically profiled samples; 16S rRNA gene, metagenomic, metatranscriptomic and cytokine profiles identified differential levels of *Lactobacillus crispatus*, BVAB1, *Sneathia amnii*, TM7-H1, and additional taxa associated with preterm deliveries.**
  51. Zhou, W. et al. Longitudinal multi-omics of host–microbe dynamics in prediabetes. *Nature* <https://doi.org/10.1038/s41586-019-1236-x> (2019). **HMP2 prediabetes study of 106 participants spanning 1,092 visits, profiling host transcriptomes, metabolomes, cytokines, and proteomes, as well as microbial taxonomic and genomic changes during healthy periods, respiratory viral infections, immunizations, and other perturbations; most molecular profiles were personalized, perturbed during infections and immunizations, and associated with changes in insulin sensitivity.**
  52. Behrman, R. E. & Butler A. S. (eds.) *Preterm Birth: Causes, Consequences, and Prevention* (National Academies Press, 2007).
  53. York, T. P., Eaves, L. J., Neale, M. C. & Strauss, J. F. III. The contribution of genetic and environmental factors to the duration of pregnancy. *Am. J. Obstet. Gynecol.* **210**, 398–405 (2014).
  54. Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. *Lancet* **388**, 3027–3035 (2016).
  55. Mor, G., Aldo, P. & Alvero, A. B. The unique immunological and microbial aspects of pregnancy. *Nat. Rev. Immunol.* **17**, 469–482 (2017).
  56. Romero, R., Dey, S. K. & Fisher, S. J. Preterm labor: one syndrome, many causes. *Science* **345**, 760–765 (2014).
-

57. Jefferson, K. K. The bacterial etiology of preterm birth. *Adv. Appl. Microbiol.* **80**, 1–22 (2012).
  58. Serrano, M. G. et al. Racioethnic diversity in the dynamics of the vaginal microbiome during pregnancy. *Nat. Med.* <https://doi.org/10.1038/s41591-019-0465-8> (2019). **HMP2 term birth study of 613 pregnant women, 1,969 non-pregnant women, and an additional 90 pregnant women followed longitudinally profiling vaginal, buccal, blood, urine, and rectal samples; shifts toward *Lactobacillus* -dominated communities tended to occur early during pregnancy, particularly in women of African or Hispanic descent.**
  59. DiGiulio, D. B. et al. Temporal and spatial variation of the human microbiota during pregnancy. *Proc. Natl Acad. Sci. USA* **112**, 11060–11065 (2015).
  60. Callahan, B. J. et al. Replication and refinement of a vaginal microbial signature of preterm birth in two racially distinct cohorts of US women. *Proc. Natl Acad. Sci. USA* **114**, 9966–9971 (2017).
  61. Kindinger, L. M. et al. The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk. *Microbiome* **5**, 6 (2017).
  62. Brown, R. G. et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. *BMC Med.* **16**, 9 (2018).
  63. Jefferson, K. K. et al. Relationship between vitamin D status and the vaginal microbiome during pregnancy. *J. Perinatol.* <https://doi.org/10.1038/s41372-019-0343-8> (2019).
  64. Zhou, S. S., Tao, Y. H., Huang, K., Zhu, B. B. & Tao, F. B. Vitamin D and risk of preterm birth: Up-to-date meta-analysis of randomized controlled trials and observational studies. *J. Obstet. Gynaecol. Res.* **43**, 247–256 (2017).
  65. Huang, H. et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature* **547**, 173–178 (2017).
  66. Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* **55**, 205–211 (2005).
  67. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc. Natl Acad. Sci. USA* **104**, 13780–13785 (2007).
  68. Kugathasan, S. et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. *Lancet* **389**, 1710–1718 (2017).
  69. Narula, N. et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. *Inflamm. Bowel Dis.* **23**, 1702–1709 (2017).
  70. Jeon, S. R., Chai, J., Kim, C. & Lee, C. H. Current evidence for the management of inflammatory bowel diseases using fecal microbiota transplantation. *Curr. Infect. Dis. Rep.* **20**, 21 (2018).
  71. Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol.* **13**, R79 (2012).
  72. Hall, A. B. et al. A novel *Ruminococcus gnavus* clade enriched in inflammatory bowel disease patients. *Genome Med.* **9**, 103 (2017).
  73. Schirmer, M. et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nat. Microbiol.* **3**, 337–346 (2018).
  74. Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat. Microbiol.* **4**, 293–305 (2019).
  75. Mallick, H. et al. Predictive metabolomic profiling of microbial communities using amplicon or metagenomic sequences. *Nat. Commun.* (in the press).
-

76. Franzosa, E. A. et al. Species-level functional profiling of metagenomes and metatranscriptomes. *Nat. Methods* **15**, 962–968 (2018).
  77. McIver, L. J. et al. bioBakery: a meta’omic analysis environment. *Bioinformatics* **34**, 1235–1237 (2018).
  78. Willing, B. P. et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology* **139**, 1844–1854.e1841 (2010).
  79. Gevers, D. et al. The treatment-naïve microbiome in new-onset Crohn’s disease. *Cell Host Microbe* **15**, 382–392 (2014).
  80. Cowie, C. C. et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. *Diabetes Care* **32**, 287–294 (2009).
  81. Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. *Diabetes Care* **27**, 813–823 (2004).
  82. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **490**, 55–60 (2012).
  83. Gamble, D. R., Kinsley, M. L., FitzGerald, M. G., Bolton, R. & Taylor, K. W. Viral antibodies in diabetes mellitus. *BMJ* **3**, 627–630 (1969).
  84. Mehta, S. H. et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann. Intern. Med.* **133**, 592–599 (2000).
  85. Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell* **148**, 1293–1307 (2012).
  86. Piening, B. D. et al. Integrative personal omics profiles during periods of weight gain and loss. *Cell Syst.* **6**, 157–170 e158 (2018).
  87. Schüssler-Fiorenza Rose, S. et al. A longitudinal big data approach for precision health. *Nat. Med.* **25**, 792–804 (2019). **HMP2 Integrative Personalized ’Omics Profiling of 109 individuals enriched for risk of type 2 diabetes studied genomically, immunologically, transcriptomically, proteomically, metabolomically, and using wearable monitoring; multiple molecular pathways were associated with metabolic, cardiovascular and oncological pathophysiology, and a subset were predictive of insulin resistance.**
  88. Wilkinson, M. D. et al. The FAIR Guiding Principles for scientific data management and stewardship. *Sci. Data* **3**, 160018 (2016).
  89. NIH Human Microbiome Portfolio Analysis Team. A review of 10 years of human microbiome research activities at the US National Institutes of Health, Fiscal Years 2007–2016. *Microbiome* **7**, 31 (2019).
-